bluebird bio Inc Shares Up Sharply Following Positive Drug Data

Shares of bluebird bio Inc BLUE are trending higher Tuesday morning following an announcement of positive data for its LentiGlobin BB305 drug.

The company announced data from eight subjects treated with LentiGlobin BB305.

“In the first four subjects, each of whom had at least three months of follow up, treatment with LentiGlobin BB305 drug product resulted in sufficient hemoglobin production to reduce or eliminate the need for transfusion support among patients with beta-thalassemia major who would otherwise require chronic blood transfusions.”

Following the announcement shares of blue bird are up 53% Tuesday morning.